CD274 and cancer: If PDL1 is a CSC marker, with stem-like properties and EMT signatures [15,16,17,18,19,20], then anti-PD1/L1 should be more effective for the treatment of certain cancer subtypes with those very CSC phenotypes and EMT pathways than without.